title: A 12 versus 6-week course of bacillus Calmette-Guerin prophylaxis for the treatment of high risk superficial bladder cancer.
abstract: OBJECTIVE
  We examined the efficacy of a 12-week prophylactic course of bacillus Calmette-Guerin (BCG) on superficial bladder cancer.
  
  
  METHODS
  From August 1992 until July 1994, 70 evaluable patients 41 to 80 years old (mean age 68.5) with high risk transitional cell carcinoma of the bladder were prospectively randomized to a 12-week prophylactic course of BCG (group 2) versus a traditional 6-week course (group 1). Mean followup was 28 months.
  
  
  RESULTS
  A 70% tumor-free rate (21 patients) and mean interval of 12.9 months to recurrence were achieved in group 2 compared to 55% (22 patients) and 12.3 months, respectively, in group 1. Group 2 patients had an overall longer disease-free survival, although no statistical significance was achieved. A subgroup of patients with stage Ta cancer in whom at least 1 tumor was resected 12 month before treatment showed the most benefit from long-term prophylactic treatment in terms of disease-free survival. Side effects were only slightly more prominent in group 2, rendering the longer course fairly acceptable.
  
  
  CONCLUSIONS
  Our findings suggest a difference for better overall results with the 12-week course of BCG. However, a larger number of patients are needed to demonstrate a statistically significant difference between the 2 groups.
authors.affiliation: Department of Urology, Carmel Medical Center, Haifa, Israel.
authors.forename: I E
authors.initials: IE
authors.lastname: Gruenwald
authors.forename: A
authors.initials: A
authors.lastname: Stein
authors.forename: R
authors.initials: R
authors.lastname: Rashcovitsky
authors.forename: G
authors.initials: G
authors.lastname: Shifroni
authors.forename: A
authors.initials: A
authors.lastname: Lurie
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000517:prevention & control* / Q000556:secondary; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000517:prevention & control*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine